Business Wire

THALES

28.2.2024 09:01:27 CET | Business Wire | Press release

Share
Eseye Selects Thales to Streamline IoT Deployments With Seamless Connectivity Management

Eseye, a global IoT connectivity solutions provider, has selected Thales to accelerate and simplify worldwide IoT deployment with a seamless connectivity solution. Thales pioneering solution enables Eseye to automatically connect IoT devices with the most appropriate profile the first time they are powered up and in-life. Thales Adaptive Connect (TAC) based on eSIM (embedded SIM) technology that drastically simplifies the management of IoT devices lifecycle. It is the first market-ready solution that eliminates the need to configure mobile subscriptions in the factory, or for technicians to visit them in the field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228389495/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

@Thales

Eseye provides IoT cellular connectivity services worldwide, and TAC brings connectivity management of IoT devices remotely to make it far easier for its customers to roll-out and support major projects in areas such as: smart utilities, supply chains, logistics, and automotive. Indeed, any kind of IoT device can be deployed and connected in any region or country without being configured beforehand.

TAC is remotely managing the eSIM automatic configuration to provide the best local connectivity from its first usage and throughout its lifespan on the field. With Thales, Eseye can ensure they all connect to the preferred mobile network whenever it is needed. For example, deployed IoT devices can be switched to another mobile network remotely, over-the-air, at any time. The Thales solution fully complies with GSMA eSIM IoT standard SGP.32, ensuring security, reliability, and future proof capability for massive IoT use cases.

Thanks to the Thales connectivity offer for eSIM-based devices, Eseye will be able to operate and manage flexible, end-to-end connectivity from the factory to the field, and throughout the device lifecycle. Which means the entire operation, including manufacturing, logistics, and connectivity, is streamlined and simplified.

“Eseye are delighted to be partnering with Thales to take forward this leading-edge, innovative new IoT solution. Combining SGP.32 and SGP.41 support will ensure future IoT device deployments can deliver optimum efficiency and value to our customers. Not only do Enterprise customers get a completely future proofed eSIM platform, but it also enables maximum choice of either personalising devices for local mobile networks ahead of deployment or using TAC to do this for them in the field” said Adam Hayes, Chief Operating Officer at Eseye.

"Eseye is a dynamic partner with whom we have also worked on a Proof of Concept for customers interested in in-factory provisioning (IFPP) for their devices. This enables profiles to be securely provisioned during the device manufacturing process. For example, a blood sugar monitor device that has been configured at the factory will have a substantially longer battery life since there is no need for an in-field local profile download. This solution, which meets the latest market specifications (SGP.41), retains all of the benefits of an automatic and cost-effective connection to the preferred local network," said Guillaume Lafaix, VP of Connectivity Solutions and Embedded Products at Thales.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000[1] employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

[1] Excluding the Transport business

PLEASE VISIT
Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228389495/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye